Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2017-06-28 Regulatory Filings
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience leads $45M financing round
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and contains an announcement from Arix Bioscience Plc regarding leading a $45 million Series B financing round for LogicBio Therapeutics. This is a specific corporate action related to financing and investment in another company, which falls under Capital/Financing Update (CAP). While it is distributed via RNS, the core content is a financing announcement, making CAP the most specific classification. It is not a general regulatory filing (RNS) because the content is highly specific to a transaction.
2017-06-28 English
Arix Bioscience in $20M Mitoconix Bio fundraise
Share Issue/Capital Change Classification · 1% confidence The document is identified by the presence of an 'RNS Number' and the explicit statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details Arix Bioscience's participation in a $20 million Series A financing round for Mitoconix Bio, which is an announcement regarding a financing activity (investment). While it relates to capital/financing (CAP), the primary nature of this specific document format, being distributed via the London Stock Exchange's regulatory news service (RNS), makes 'Regulatory Filings' (RNS) the most appropriate general classification for this type of market announcement, especially since 'CAP' is defined more broadly for company fundraising activities rather than specific investment participation announcements distributed via RNS. Given the strong RNS identifier and the nature of the announcement (a corporate event disclosure), RNS is the best fit as a specific regulatory disclosure channel.
2017-06-27 English
Arix notes Artios collaboration
M&A Activity Classification · 1% confidence The document begins with an 'RNS Number' and is dated June 12, 2017. The content describes Arix Bioscience noting an announcement by its group business, Artios Pharma, regarding a new collaboration and option agreement for cancer target development. This is a general corporate announcement distributed via the London Stock Exchange's news service (RNS). Since it is a general regulatory announcement that doesn't fit specific categories like ER, DIV, or DIRS, and it is clearly marked as an RNS release, the most appropriate classification is Regulatory Filings (RNS). The document length is relatively short (3814 chars), but the content is the announcement itself, not just a notice that a report is attached, making RNS a better fit than RPA.
2017-06-12 English
Result of AGM
AGM Information Classification · 1% confidence The document explicitly states its purpose in the title: 'Results of Annual General Meeting'. It details that the meeting was held on June 5, 2017, and provides a full breakdown of the poll results for ordinary and special resolutions proposed at that meeting. This content directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including the results thereof.
2017-06-05 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Director/PDMR Shareholding' and details the purchase of ordinary shares by the Chief Executive Officer, Chief Financial Officer, and Chairman. This type of filing, reporting personal share transactions by company directors and executives (insiders), directly corresponds to the definition of Director's Dealing. The presence of 'RNS Number' and the closing 'END' structure suggests it is a regulatory announcement, but the specific content points overwhelmingly to Director's Dealing (DIRS) rather than a general regulatory filing (RNS).
2017-06-05 English
Arix to present at Jefferies Healthcare Conference
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and contains an announcement from Arix Bioscience Plc regarding its CEO presenting at the Jefferies 2017 Global Healthcare Conference. This is a general corporate announcement about management participation in an external event, not a core financial report (like 10-K, IR, ER) or a specific regulatory filing like insider trading (DIRS) or dividend declaration (DIV). Since it is a general, time-sensitive corporate news item distributed via the London Stock Exchange's news service (indicated by 'RNS Number' and 'The company news service from the London Stock Exchange'), and it doesn't fit neatly into the other specific categories (like AGM-R, MANG, CT, etc.), the most appropriate classification is the general regulatory announcement fallback category, RNS.
2017-05-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.